Introduction
Coronavirus SARS-CoV-2 is currently causing a pandemic of COVID-19, with more than
3 million confirmed cases around the globe identified as of June 2020. During these
extraordinary times, caring for patients with COVID-19 and underlying COPD poses particular
challenges. Certain treatments relevant to treating patients with COPD, such as nebulised
bronchodilators and non-invasive ventilation (NIV), are thought to carry an increased
risk of viral spread via aerosols. Uncertainties on whether to use systemic steroids
have entered the minds of intensive care and respiratory communities. Moreover, questions
regarding which life-sustaining treatments to start, when to start them and even whether
to start them are faced by clinicians on a daily basis. Treating COPD effectively
in the context of COVID-19 is important since patients with COPD are at an increased
risk of poor outcomes. Here, we summarise current viewpoints from four European countries
on how to care for patients with COPD and COVID-19.
We will address the following specific questions:
Are patients with COPD at an increased risk of COVID-19?
Should COVID-19 be considered a COPD exacerbation?
What is the optimal medical treatment for a patient with COPD and COVID-19?
Which ventilatory support should be provided to patients with COPD and COVID-19?
What other supportive treatments should be offered to patients with COPD and COVID-19?
How should end-of-life care be delivered in patients with COPD during the COVID-19
pandemic?
Are patients with COPD at an increased risk for COVID-19?
Since patients with COPD are vulnerable to viral respiratory tract infections, and
COPD is generally a disease of the elderly, many had expected that patients with COPD
would have a considerably increased risk of acquiring COVID-19. Studies so far, however,
indicated only around 2% of patients admitted to hospital with COVID-19 infection
in China had underlying COPD,1 2 while the prevalence of COPD in China ranges from
5% to 13%.3 Indeed, COPD was not the most commonly reported comorbidity seen in patients
with COVID-19.1 However, while the low percentage suggests COPD is not a risk factor
for acquiring COVID-19, the size of the pandemic will still affect many patients with
COPD. What’s more, patients with COPD and COVID-19 have a worse clinical outcome compared
with patients with other comorbidities2: patients with COPD and current smokers have
an increased risk for severe disease.2 4 Moreover, both patients with COPD and smokers
have an increased risk of dying from COVID-19.2 4
Should a COVID-19 infection be considered a COPD exacerbation?
Coronaviruses are recognised seasonal causes of acute exacerbations of COPD (AECOPD).
There remains controversy as to whether COVID-19 in a patient with underlying COPD
should be considered a COPD exacerbation. This stems from our current definition of
an exacerbation being a clinical diagnosis based on a change in symptoms needing a
change in treatment.5 Thus, a patient with COVID-19 and COPD presenting with increased
cough and breathlessness requiring treatment would fulfil the current definition of
exacerbation. However, it is clear from imaging and postmortem studies that the pathology
of a typical AECOPD is very different from the viral pneumonia typical of COVID-19.6
Thus, conceptually, COVID-19 in a patient with COPD is likely a very different pathophysiological
process.
What is the medical treatment of a patient with COPD and COVID-19?
Though COVID-19 might not be a typical AECOPD, physicians must take the underlying
COPD into consideration when treating COVID-19 in COPD. Also, diagnosing COVID-19
in a patient with COPD does not preclude a concomitant AECOPD and the need for treatment
for this. Specific to treating patients with COPD is the necessity for bronchodilators,
the beneficial effects of NIV and the frequent need for antibiotics. Concerns have
been raised as to whether and how these therapies should be offered to patients with
COPD during the pandemic.
Antibiotics
Outside the context of COVID-19, not all AECOPDs should be treated with antibiotics,5
and current guidelines suggest reserving antibiotics for AECOPDs that require hospitalisation
or ventilatory support.7 Overall, bacterial coinfections are uncommon in COVID-19:
recent meta-analysis has shown that only 8% of patients had a bacterial/fungal coinfection.8
The risk of coinfections increases with the severity of COVID-19: a cohort study on
risk factors for in-hospital death from COVID-19 found that 50% of non-survivors experienced
secondary infections and that ventilatory-associated pneumonia was seen in 31%.9 Since
it may be difficult to distinguish SARS-CoV-2 infections from a bacterial pneumonia
and because patients with COPD are at risk for bacterial (super)infections, we suggest
treating hospitalised patients with COPD and COVID-19 and respiratory symptoms with
broad-spectrum antibiotics, guided by local/national guidelines for treating pneumonia.
This is in line with the current WHO treatment guideline for severe COVID-19.10 Microbiological
analysis, such as sputum culture, should be performed on admission and it may then
be reasonable to stop antibiotics in the absence of a coinfection.
Bronchodilators and nebulisation
Bronchodilators are frequently given via nebuliser in hospitalised patients with COPD.
The British Thoracic Society (BTS) guideline on treating patients with COPD and COVID-19
supports the use of nebulisers, claiming there is no evidence supporting an increased
risk of viral transmission and, second, that aerosols surrounding the nebuliser come
from the nebuliser not from patients.11 However, the meta-analysis suggesting nebulisers
do not increase viral transmission has some methodological concerns.12 It is based
on one study with a very small sample size, a second study investigating a variety
of interventions and on a third in which infections began before exposure to nebulisation.
The BTS guideline was also based on a methodological study showing that nebulisers
predominantly produce aerosols not droplets, also used to suggest that nebulisation
was safe.13 Viral transmission was not the subject of this investigation and since
it remains open to debate whether droplets or aerosols can contain SARS-CoV-2, we
do not think these results should be used as reassurance of no risk of transmission.
Alternative modes of inhalation are available, including pressurised metered-dose
inhalers (pMDI) used with a spacer. In AECOPD pMDIs are not inferior to nebulisers.14
Long-acting dual bronchodilators may be preferred; some also have a fast onset of
action, and are more effective with a longer duration of action. There are currently
two long-acting pMDI combinations available which can be used with a spacer.
No maximum dosing has been provided for nebulised short-acting bronchodilators and
very high doses are often administered for AECOPD. We suggest doubling the maximum
maintenance dose of long-acting bronchodilators, reflecting the high doses of short-acting
bronchodilators often used in clinical practice. Since the safety of nebulisers is
controversial and given that there is a suitable alternative, we recommend bronchodilators
administered by pMDI and spacer over the use of nebuliser treatment in symptomatic
patients with COPD and COVID-19. Nebulised treatment should be reserved for those
situations in which pMDI with spacer is not possible, such as patients with severe,
life-threatening disease or those unable to use a pMDI. For healthcare workers, respiratory
masks (FFP-3 or equivalent) and other personnel protective equipment should be used
during aerosol-generating procedures such as nebulisers.15
Systemic corticosteroids
It is recognised that not all AECOPDs need to be treated with systemic corticosteroids.5
Eosinophil-based steroid treatment has been advocated for both stable COPD and AECOPD;
however, the use of this strategy in patients with COPD and COVID-19 has not been
tested. Until recently, the efficacy of corticosteroids in general for treating COVID-19
was inconclusive, though a cohort study suggested steroids might improve clinical
outcome in patients with COVID-19.16 Recent, preliminary results from the Randomized
Evaluation of COVID-19 Therapy (RECOVERY) trial have shown that dexamethasone improves
mortality in patients with COVID-19 requiring respiratory support.17 The WHO recommended
against the use of steroids previously,10 but is now updating treatment guidelines
to include dexamethasone or other corticosteroids.
Corticosteroids are beneficial to patients with severe AECOPD, especially in patients
requiring ventilatory support, in whom steroids reduce ventilation days and NIV failure;
therefore, it is reasonable to treat patients with COPD and severe COVID-19 with course
of corticosteroids. The RECOVERY regimen of 6 mg once daily could be used until more
evidence is provided to guide treatment in patients with COPD with COVID-19.
Which ventilatory support should be provided to patients with COPD with respiratory
failure?
Approximately, 14% of patients with a SARS-CoV-2 infection will develop severe disease
requiring oxygen therapy and 5% will require transfer to the intensive care unit (ICU)
and ventilatory support.5 In patients with COPD, several ventilatory support strategies
can be considered, depending on the type of respiratory failure (ie, hypoxaemic or
hypercapnic respiratory failure), and on local practice and availability of resources.18
Patients with hypoxaemic COPD and COVID-19 should be given controlled oxygen therapy
as the first step.18 If hypoxaemia is insufficiently controlled with maximum oxygen
supplementation, high-flow nasal cannula (HFNC) or CPAP with high oxygen flow should
be considered. HFNC has recently been suggested as a management option in patients
with COVID-19 with acute hypoxaemic respiratory failure.18 Reduction of hypercapnia
and work of breathing might be additional benefits of HFNC in patients with COPD and
COVID-19.19 20 However, HFNC is an open system and expiration cannot be filtered.
A surgical mask can be placed over the nasal cannula to limit aerosol spread.15 Besides
HFNC, CPAP with a high fraction of inspired oxygen (FiO2) might be an option to treat
hypoxaemic respiratory failure. CPAP provides a certain level of positive end-expiratory
pressure, which might be a useful add-on to oxygen supplementation. Furthermore, it
is possible to filter expiration with CPAP and thus limit viral spread.
In patients with COPD with acute (on chronic) hypercapnic respiratory failure, NIV
should be considered.21 There are no data showing that HFNC is equivalent and thus
in this population we recommend using NIV first line. Transmission of virus can be
reduced by using a non-vented mask with the exhaled air passing through a bacterial/viral
filter before entering the room. Second, an expiration system with an active valve
can be used and the oxygen supply can be connected close to the mask, so that a higher
FiO2 can be reached.22 Before starting NIV, the patient’s willingness to undergo invasive
mechanical ventilation (IMV), if NIV fails, should be discussed. Previous studies
have shown that IMV after NIV failure is associated with higher mortality in AECOPD,23
though this association has not been shown in COVID-19.24
IMV should be instituted in patients with severe hypoxaemic respiratory failure or
after NIV failure.18 Particularly in COPD, this decision should be made carefully,
as it is known that in-hospital mortality with IMV in AECOPD is high.25 Mortality
is even higher for patients with COPD with severe COVID-19,2 and the prolonged duration
of mechanical ventilation seen in patients with COVID-19 might be particularly detrimental
to the future health status of patients with COPD. In communicating IMV with patients
with COPD, the risks and benefits should be explained clearly, and patients’ wishes
and preferences regarding life-prolonging therapies should be explored such that known
risk factors for poor outcomes of IMV in COPD26 can be weighed in a process of shared
decision-making.
Finally, clinicians might be faced with patients on home mechanical ventilation admitted
to the hospital with COVID-19. Their ventilatory support should be continued in hospital,
with precautions to limit viral spread. Home treatment, supported by telemonitoring,
might be preferred. The value and goals of a hospital admission should be discussed
in the low likelihood of surviving a long period of ICU admission.
Which other supportive treatments should be offered to patients with COPD and COVID-19?
SARS-CoV-2 infections may have wide-ranging detrimental effects on patients’ well-being.
The strict isolation required may amplify feelings of solitude and hopelessness. Also,
patients with SARS-CoV-2 often complain of loss of taste and appetite, increasing
the risk of unintentional weight loss. Regular exercise, let alone rehabilitation,
is difficult during a hospital stay.
Hospital treatment should therefore include dietary, as well as emotional and spiritual
support. Early mobilisation is encouraged in recent COVID-19-specific physiotherapy
guidelines, while airway clearance techniques should be provided prudently as they
carry the risk of aerosol spread.27 After discharge, discharge bundles should be continued
to ensure smooth transfer from hospital to home care and to reduce the risk of readmission.5
Although pulmonary rehabilitation (PR) is recommended for people with COPD, rehabilitation
in general should be offered to all patients with COVID-19 and certainly after ICU
admission. The prolonged ICU stay is known to have significant impact on both physical
and emotional well-being and patients may have accompanying symptoms of post-traumatic
stress disorder.28
Social distancing and concerns about residual viral transmission may limit possibilities
for centre-based PR and physiotherapy. Home-based, unsupervised PR might be a solution
in these times of social distancing.5 However, exercise-induced desaturation and cardiac
arrhythmias associated with COVID-19 may make it difficult to guarantee the safety
of unsupervised training. As soon as centre-based PR is possible, patients should
again flow into such supervised programmes for optimal benefit.
How should end-of-life care be delivered in patients with COPD during the COVID-19
pandemic?
As described above, patients with COPD are at an increased risk for a poor outcome
with COVID-19 and may choose to forego life-sustaining treatments. Ideally, identifying
and discussing goals and preferences for future medical treatment and care, known
as advance care planning (ACP), should have been undertaken before hospital admission.
In practice, ACP is uncommon in COPD.5 The challenge in the current SARS-CoV-2 pandemic
is addressing palliative care needs in times of crisis, at a time when preventing
unwanted life-sustaining treatments is paramount. We stress that discussions concerning
triage for intensive care treatment under resource scarcity should not be included
in this process of ACP.
ACP also includes communication about end-of-life care. We advise timely communication
about end-of-life care.29 Patients may have worries about suffocation and the process
of dying. Fear is common in patients in respiratory distress and could be pharmacologically
treated with anxiolytics, such as lorazepam.30 Opioids such as morphine can be used
to manage dyspnoea and should not be delayed to the dying phase.30 In patients with
suffering despite optimal symptom management, palliative sedation can be discussed
with patients and their relatives. Care for relatives needs specific attention in
the SARS-CoV-2 pandemic: social distancing limits hospital visits and the necessity
of personal protective equipment imposes severe restraints on saying goodbye to loved
ones, thereby increasing the risk for complicated grief. Therefore, bereavement care
needs to be considered.
Conclusion
This article provides an overview on how to manage patients with COPD and COVID-19
during the SARS-CoV-2 pandemic. Key points have been summarised in table 1. Caring
for patients with COPD and COVID-19 poses special challenges for healthcare workers.
Not only are they faced with severely ill, often elderly, patients who can deteriorate
rapidly and have a poor prognosis, they are working in an environment with increased
risk of being infected themselves. The suggestions put forward in this article provide
a framework for those working in such challenging conditions. We acknowledge that
such a viewpoint provides a momentary snapshot of current clinical practice and evidence
how to treat COVID-19 effectively in patients with COPD is limited. Knowledge of COVID-19
is rapidly accumulating; therefore, the discussion on how to best treat patients with
COPD and COVID-19 should continue and we invite the respiratory community to share
best practices online.
Table 1
Caring for patients with COPD and COVID-19
1
There are no data to suggest that COPD is a risk factor for acquiring SARS-CoV-2.
2
In patients with COVID-19, COPD is associated with an increased risk of poor outcome.
3
A COVID-19 chest infection in a person with underlying COPD is likely a very different
process from an acute exacerbation of COPD. However, the diagnosis of COVID-19 does
not exclude a coexisting AECOPD. Furthermore, treatment of COVID-19 should take the
underlying COPD into account.
4
Antibiotics are advisable in patients with COPD requiring hospitalisation for SARS-CoV-2
chest infection, especially when ventilatory support is needed.
5
Bronchodilators administered by pMDI and spacer are preferred to nebuliser treatment
in patients with COPD and COVID-19 and respiratory symptoms. We suggest using long-acting
bronchodilators, if needed at twice the frequency of maintenance treatment.
6
Nebuliser treatment should be reserved for those patients with life-threatening disease
or those unable to use a pMDI and a spacer. Attention should be paid to preventing
airborne transmission in such cases.
7
A course of systemic corticosteroids is advisable in patients with COPD and an AECOPD
who require hospitalisation for a SARS-CoV-2 chest infection.
8
Regarding the choice of ventilatory support, it is of utmost importance that patients’
wishes and decisions made with regard to ventilatory support and/or ICU admission
and intubation are clear.
9
NIV should be offered to patients with COPD and COVID-19 and acute (on chronic) hypercapnic
respiratory acidosis. Care should be taken to limit viral spread by using non-vented
masks with exhaled air passing a bacterial/viral filter before entering the room.
10
Chronic NIV should be continued in patients with COPD on home NIV when they present
with COVID-19. Home treatment might be an option.
11
We suggest HFNC or CPAP with high FiO2 in patients with COPD and COVID-19 and acute
hypoxaemic respiratory failure, if oxygen therapy fails. Care should be taken to limit
viral spread by using surgical masks over the nasal cannulas. With CPAP, exhalation
can be filtered before entering the room.
12
Rapid intubation and invasive mechanical ventilation should be provided if patients
do not respond adequately to non-invasive support, depending on prior discussions
and decisions about escalation of treatment.
13
Hospitalised patients with COPD and COVID-19 should be monitored for unintentional
weight loss and dietary support should be offered accordingly.
14
The use of airway clearance techniques in patients with COPD and COVID-19 should be
provided prudently to reduce the risk of viral transmission.
15
Early mobilisation in patients with COPD and COVID-19 is very important.
16
It is important to offer psychological and spiritual support to patients with COPD
and COVID-19 during hospital admission, as well as during follow-up.
17
Pulmonary rehabilitation should be offered to all patients with COPD and COVID-19
after discharge from the hospital, perhaps starting in an alternative form as long
as social distancing is still required.
18
We suggest screening all patients with COVID-19, especially after ICU stay, for emotional
and functional limitations and to offer rehabilitation when indicated.
19
Timely advance care planning in patients with COPD should be provided, including patient–physician
communication about patients’ values, goals and preferences regarding life-sustaining
treatments, as well as addressing worries about the dying phase and palliative treatment
options. Timeliness and diligence in this are even more important and challenging
during this time of COVID-19 pandemic.
20
Appropriate management of symptoms at the end of life in patients with COPD and COVID-19
is crucial, including management of anxiety, dyspnoea and palliative sedation as needed.
21
We suggest considering bereavement care for loved ones of deceased patients with COPD
and COVID-19, since they may be at an increased risk for complicated grief.
AECOPD, acute exacerbations of COPD; HFNC, high-flow nasal cannula; ICU, intensive
care unit; NIV, non-invasive ventilation; pMDI, pressurised metered-dose inhaler.